FDA MedWatch - 2009 Safety Alerts for Human Medical Products

Raptiva (efalizumab)
Audience: Dermatological healthcare professionals, patients
Genentech and FDA notified healthcare professionals of the voluntary, phased withdrawal of Raptiva, a medication for treatment of psoriasis, from the U.S. market due to a potential risk to patients of developing progressive multifocal leukoencephalopathy (PML). By June 8, 2009, Raptiva will no longer be available in the United States. Prescribers are being asked not to initiate Raptiva treatment for any new patients. Prescribers should immediately begin discussing with patients currently using Raptiva how to transition to alternative therapies. The FDA strongly recommends that patients work with their health care professional to transition to alternative therapies for psoriasis.

Read the complete MedWatch 2009 Safety Summary, including links to the Dear Healthcare Professional letter, the Dear Patient letter and the FDA statement, at: http://www.fda.gov/medwatch/safety/2009/safety09.htm#Raptiva

abrir aquí para acceder a la comunicación FDA y desde allí acceder a las notificaciones dirigidas a profesionales, público, y técnicas:
FDA MedWatch - 2009 Safety Alerts for Human Medical Products